[1]何霁云 赵丽明 刘凯.数字疗法用于中国成人高血压患者进行自我管理的评估[J].心血管病学进展,2023,(3):270.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.018]
　HE Jiyun,ZHAO Liming,LIU Kai.Assessment of digital therapeutics-based self-management in Chinese hypertensive patients[J].Advances in Cardiovascular Diseases,2023,(3):270.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.018]
点击复制

数字疗法用于中国成人高血压患者进行自我管理的评估()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年3期
页码:
270
栏目:
论著
出版日期:
2023-03-25

文章信息/Info

Title:
Assessment of digital therapeutics-based self-management in Chinese hypertensive patients
作者:
何霁云1 赵丽明2 刘凯3
（1.成都市第一人民医院心内科，四川 成都 610041；2.四川大学华西医院西藏成办分院心内科，四川 成都 610041；3.四川大学华西医院心内科，四川 成都 610041）
Author(s):
HE Jiyun1; ZHAO Liming2; LIU Kai3
(1.Department of Cardiology,Chengdu Frist People’s Hospital,Chengdu 610041,Sichuan,China; 2.Department of Cardiology,Chengdu Office Hospital of Tibet Autonomous Region People’s Government,West China Hospital,Sichuan University,Chengdu 610041,Sichuan; 3.Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan)
关键词:
高血压; 自我管理; 数字疗法; 控制率; 参与度
Keywords:
Hypertension; Self-management; Digital therapeutics; Control rate; Engagement
DOI:
10.16806/j.cnki.issn.1004-3934.2023.03.018
文献标志码:
A
摘要:
目的 探讨数字疗法用于中国成人高血压患者自我管理的可行性及效果评估。方法 纳入2021年5月1日-2021年12月31日使用数字疗法进行自我管理的高血压患者进行回顾性分析。根据基线收缩压（SBP）值将受试者分为正常血压组（SBP＜130mmHg，1mmHg=0.133kPa），正常高值血压组（SBP130-139mmHg），1级高血压组（SBP140-159mmHg），2级高血压组（SBP160-179mmHg），采用混合效应模型分析血压管理效果。结果 队列共纳入1131人，最终数据可用于分析者514人，年龄中位数（四分位间距，IQR）51（42-60）岁。正常血压组共237人(46.1%),正常高值血压组共118人(22.9%)，1级高血压组共96人(18.6%)，2级高血压组共63人(12.2%)，各组受试者在26周时SBP降幅（均值标准误，SEM）分别为2.9(0.9)、14.2(1.5)、25.9(2.1)和35.3 (3.2)mmHg。基线SBP＞140mmHg者共159人（30.9%），在26周时血压控制率为87.4%。校正了年龄，性别，BMI，腰围，吸烟，焦虑，高脂血症，糖尿病，冠心病，卒中，房颤，慢性心力衰竭，慢性肾病，动脉粥样硬化性心血管病(ASCVD)风险、是否服药降压药，数字疗法参与度更高与SBP降幅更大相关（P＜0.001）。观察到57人在随访过程中出现血压异常升高（SBP≥160mmHg），参与度更高与更少出现血压异常升高相关（P＜0.001）。结论 使用数字疗法进行高血压自我管理可以帮助改善高血压的控制率，且能及时发现血压异常升高的情况进行及时处理。
Abstract:
Objective To explore the feasibility and efficacy of digital therapeutics for self-management in Chinese adult hypertension patients. Methods Patients agreed to use digital therapeutics for self-management from May 1, 2021 to December 31, 2021 were included in a retrospective analysis. Subjects were divided based on baseline systolic blood pressure (SBP) into normal blood pressure group (SBP < 130mmHg), high-normal blood pressure group (SBP130-139mmHg), grade 1 hypertension group (SBP140-159mmHg), and grade 2 hypertension group (SBP160-179mmHg). A mixed model was used to analyze the effect of blood pressure management. Results A total of 1131 subjects were included in the cohort, and the final data were available for analysis in 514 subjects with a median age (Interquartile range, IQR) of 51 (42-60) years. 237 patients (46.1%) in the normal blood pressure group, 118 patients (22.9%) in the high-normal blood pressure group, 96 (18.6%) in the grade 1 hypertension group, 63 (12.2%) in the grade 2 hypertension group. The SBP decrease (Standard error of mean, SEM) of each group at week 26 was 2.9 (0.9), 14.2(1.5), 25.9(2.1) and 35.3 (3.2)mmHg, respectively. The blood pressure control rate of 159 (30.9%) subjects with baseline SBP > 140mmHg achieved 87.4% at 26 weeks. After adjusting for age, sex, smoking, BMI, waist circumference, anxiety, diabetes, stroke, atrial fibrillation, coronary heart disease, heart failure, and chronic kidney disease, ASCVD risk and medication, higher engagement of digital therapeutics was associated with a greater reduction in SBP (P < 0.001).Fifty-seven patients were observed to have abnormally elevated blood pressure (SBP≥160mmHg) during follow-up, and higher engagement was associated with fewer abnormally elevated blood pressure (P < 0.001). Conclusion Using digital therapeutics for self-management may help to improve the control rate of hypertension, and can timely detect abnormal elevated blood pressure

参考文献/References:

[1]中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37(6):553-578.

[2]Whelton PK,Carey RM,Aronow WS,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2018,71(19):e127-e248.?#65279
[3]Tucker KL,Sheppard JP,Stevens R,et al. Self-monitoring of blood pressure in hypertension:a systematic review and individual patient data meta-analysis[J]. PLoS Med,2017,14(9):e1002389.
[4]Kario K,Harada N,Okura A. Digital therapeutics in hypertension:evidence and perspectives[J]. Hypertension,2022,79(10):2148-2158.
[5]Alessa T,Abdi S,Hawley MS,et al. Mobile apps to support the self-management of hypertension:systematic review of effectiveness,usability,and user satisfaction[J]. JMIR Mhealth Uhealth,2018,6(7):e10723.
[6]Lu X,Yang H,Xia X,et al. Interactive mobile health intervention and blood pressure management in adults[J]. Hypertension,2019,74(3):697-704.
[7]Liu K,Xie Z,Or CK. Effectiveness of mobile app-assisted self-care interventions for improving patient outcomes in type 2 diabetes and/or hypertension:systematic review and meta-analysis of randomized controlled trials[J]. JMIR Mhealth Uhealth,2020,8(8):e15779.
[8]Kaplan AL,Cohen ER,Zimlichman E. Improving patient engagement in self-measured blood pressure monitoring using a mobile health technology[J]. Health Inf Sci Syst,2017,5(1):4.
[9]Unger T,Borghi C,Charchar F,et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens,2020,38(6):982-1004.
[10]Williams B,Mancia G,Spiering W,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J,2018,39(33):3021-3104.
[11]中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[12]中国高血压联盟《家庭血压监测指南》委员会. 2019中国家庭血压监测指南[J].中华高血压杂志,2019,27(8):708-711.
[13]中华医学会心血管病学分会,中国康复医学会心脏预防与康复专业委员会,中国老年学和老年医学会心脏专业委员会,等. 中国心血管病一级预防指南[J]. 中华心血管病杂志,2020,48(12):1000-1038.
[14]张洁,马青,李蓉琼,等.手机微信软件在原发性高血压患者出院随访中的应用[J].华西医学,2017,32(1):42-45.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
　SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
　FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
　CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(3):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
　ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
　ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
　HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(3):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
　ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(3):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
　LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
　WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(3):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]

更新日期/Last Update: 2023-04-24